Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

(2020) Rajiv Agarwal et al.   EUROPEAN HEART JOURNAL

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

(2019) Hiddo J L Heerspink et al.   LANCET

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

(2019) Hiddo J L Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The global burden of kidney disease and the sustainable development goals

(2018) Valerie A Luyckx et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients

(2018) Dragana Lovre et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry

(2018) Gianluigi Savarese et al.   EUROPEAN JOURNAL OF HEART FAILURE

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance

(2018) Jana Grune et al.   HYPERTENSION

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

(2018) Jonatan Barrera-Chimal et al.   KIDNEY INTERNATIONAL

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance

(2017) Lionel Lattenist et al.   HYPERTENSION

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

(2017) Peter Kolkhof et al.   JOURNAL OF ENDOCRINOLOGY

Diabetes with early kidney involvement may shorten life expectancy by 16 years

(2017) Chi Pang Wen et al.   KIDNEY INTERNATIONAL

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

(2016) Gerasimos Filippatos et al.   EUROPEAN HEART JOURNAL

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy

(2016) Jana Grune et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials

(2016) Jie V. Zhao et al.   Journal of the American Society of Hypertension

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1

(2015) Larbi Amazit et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628

(2015) Frank Y. Ma et al.   PLoS One

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease

(2014) L. L. Huang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

(2013) Ron T Gansevoort et al.   LANCET

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

(2013) Linda F. Fried et al.   NEW ENGLAND JOURNAL OF MEDICINE

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

(2012)   AMERICAN JOURNAL OF KIDNEY DISEASES

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure

(2010) Masayuki Yamaji et al.   AMERICAN HEART JOURNAL

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE